Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2010 by National Taiwan University Hospital.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Bristol-Myers Squibb
Information provided by:
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT00597259
First received: January 9, 2008
Last updated: June 28, 2010
Last verified: June 2010
  Purpose

Although the best treatment choice for chronic hepatitis B is not clarified yet, certain therapeutic concepts could be derived from the experience of treating patients with chronic hepatitis C or human immunodeficiency virus (HIV) infection. A major advancement in treating hepatitis C or HIV infection has been the development of combination therapy. Whether the combination therapy using Peg-IFN alfa-2a plus ETV can achieve a long-term beneficial effect against ETV alone is not clarified. A prior single-arm pilot study suggested that similar combination therapy may be beneficial in patients with chronic hepatitis B. In this proposal, we thus hypothesize that the efficacy by using combination therapy with pegylated IFN alfa-2a plus ETV is superior to that by using ETV alone in that Peg-IFN may restore host immunity against HBV and prolonged ETV can maximize viral suppression.

The objective of this clinical trial is to evaluate the efficacy of the combination of Peg-IFN alfa-2a at a dose of 180 mcg administered subcutaneously per week and ETV 0.5 mg daily for 24 weeks followed by ETV 0.5 mg daily monotherapy for an additional 120 weeks versus ETV 0.5 mg daily monotherapy for 144 weeks in patients with HBeAg-positive chronic hepatitis B. It will be an open-label, randomized, comparative, multi-center clinical trial. The recruited patients will be equally randomized into two treatment groups. Treatment-free follow-up period will be 48 weeks in both groups of patients. All subjects will be assessed for loss of HBeAg, presence of anti-HBe, loss of HBsAg, presence of anti-HBs, suppression of HBV DNA, and normalization of serum ALT at the end of treatment and end of follow-up. Genotypic and virologic resistance to ETV will also be assessed at baseline and at end of years 1, 2 and 3. The primary efficacy will be HBeAg seroconversion.


Condition Intervention Phase
Chronic Hepatitis B
Drug: Pegasys plus Entecavir
Drug: Entecavir
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B

Resource links provided by NLM:


Further study details as provided by National Taiwan University Hospital:

Primary Outcome Measures:
  • HBeAg seroconversion [ Time Frame: at the end of 24 weeks post-treatment follow-up ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Serum ALT normalization, HBeAg loss, serum HBV DNA disappearance, HBsAg disappearance, histologic change, entecavir resistance [ Time Frame: At the end of treatment and 24 weeks after end of treatment ] [ Designated as safety issue: No ]

Estimated Enrollment: 294
Study Start Date: January 2008
Estimated Study Completion Date: February 2014
Estimated Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A Drug: Pegasys plus Entecavir
Pegasys 180 mcg in 0.5 mL solution administered sc once weekly for 24 weeks plus entecavir (0.5mg mg/capsule) 0.5 mg administered po daily for 24 weeks
Active Comparator: B
Entecavir Alone
Drug: Entecavir
ETV 0.5 mg daily monotherapy for 144 weeks

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

Subjects meeting all of the following criteria will be considered for entering the study:

  1. Adult male or female, 18 to 70 years of age

    • Patient must have documented positive serum HBsAg for a minimum of 6 months prior to entry into study.
    • Patients must show evidence of HBV replication and hepatitis documented by

      • Positive serum HBV DNA within 3 months prior to entry (HBV DNA >100,000 copies/mL)
      • Positive serum HBeAg within 3 months prior to entry.
      • Documented presence of abnormal alanine aminotransferase (ALT) twice within 3 months prior to entry (2 to 10 folds above the upper normal level)
      • Liver biopsy finding shows evidence of chronic hepatitis without liver cirrhosis
      • Naïve to lamivudine
  2. Compensated liver disease with the following minimum hematological and serum biochemical criteria:

    • Hemoglobin values of ≥ 12 gm/dL for both genders
    • WBC ≥ 3,000/mm3
    • Neutrophil count ≥ 1,500/ mm3
    • Platelets ≥ 100,000/ mm3
    • PT prolong < 3 sec, INR < 1.2
    • Total bilirubin ≤ 2 mg/dL
    • Albumin > 3.5 g/dL
    • Uric acid within normal ranges
    • Serum creatinine ≤ 123.76 mmol/L (≤ 1.4 mg/dL)
    • Hemoglobin A1C ≤ 8.5% for diabetic patients (whether on medication and/or controlled with diet)
  3. Thyroid stimulating hormone (TSH), within normal ranges (subjects requiring medication to maintain TSH levels in the normal range are eligible if all other inclusion/exclusion criteria are met)
  4. Negative serum antibody to hepatitis C (anti-HCV)
  5. Negative antibody to human immunodeficiency virus (anti-HIV)
  6. Alfa-fetoprotein within normal range (obtained within the previous year, or if elevated and <100 ng/ml, then a negative ultrasound for hepatocellular carcinoma within prior 3 months is required.)
  7. Subject must be willing to give written informed consent and be able to adhere to dose and visit schedules

Exclusion criteria:

Subjects presenting with any of the following will not be included in the study:

  1. Women who are pregnant or nursing
  2. Prior treatment for hepatitis with any interferon, NA or other investigational agents
  3. Prior treatment for hepatitis with immunomodulatory drug within previous 2 years
  4. Suspected hypersensitivity to interferon
  5. Have evidence of cirrhosis
  6. History of severe psychiatric disease, especially depression
  7. Concurrent malignancies (including hepatocellular carcinoma)
  8. Unstable or significant cardiovascular diseases (e.g., angina, congestive heart failure, recent myocardial infarction, severe hypertension or significant arrhythmia; subjects with ECG showing clinically significant abnormalities)
  9. Prolonged exposure to known hepatotoxins such as alcohol or drugs
  10. History of thyroid disease poorly controlled on prescribed medication
  11. Poorly controlled diabetes mellitus
  12. Have suspected or confirmed significant hepatic disease from an etiology other than HBV (e.g., alcohol, autoimmune disease etc.)
  13. Patients co-infected with hepatitis C and /or HIV
  14. Severe renal disease or myeloid dysfunction
  15. History of organ transplantation other than cornea and hair transplant
  16. Any medical condition requiring, or likely to require during the course of the study, chronic systemic administration of steroids
  17. Any other condition which in the opinion of the investigator would make the subject unsuitable for enrollment, or could interfere with the subject participating in and completing the protocol.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00597259

Contacts
Contact: Pei-Jer Chen, M.D., Ph.D. 886-2-23123456 ext 7072 peijerchen@ntu.edu.tw
Contact: Chun-Jen Liu, M.D., Ph.D. 886-2-23123456 ext 6644 cjliu@ntu.edu.tw

Locations
Taiwan
National Taiwan University Hospital Department of Internal medicine Recruiting
Taipei, Taiwan, 100
Contact: Pei-Jer Chen, M.D., Ph.D.    886-2-23123456 ext 7072    peijerchen@ntu.edu.tw   
Principal Investigator: Pei-Jer Chen, M.D., Ph.D.         
Sponsors and Collaborators
National Taiwan University Hospital
Bristol-Myers Squibb
Investigators
Principal Investigator: Pei-Jer Chen, M.D., Ph.D. National Taiwan University Hospital Department of Internal Medicine
  More Information

No publications provided

Responsible Party: Pei-Jer Chen, National Taiwan University Hospital
ClinicalTrials.gov Identifier: NCT00597259     History of Changes
Other Study ID Numbers: 200710028M, No other ID
Study First Received: January 9, 2008
Last Updated: June 28, 2010
Health Authority: Taiwan: Department of Health

Keywords provided by National Taiwan University Hospital:
hepatitis B, entecavir, pegylated interferon alfa-2a

Additional relevant MeSH terms:
Hepatitis B
Hepatitis B, Chronic
Hepatitis
Hepatitis A
Hepatitis, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Hepadnaviridae Infections
DNA Virus Infections
Peginterferon alfa-2a
Entecavir
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 21, 2014